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Abstract
Background: MicroRNA-452 (miR-452) was previously reported to be dysregulated in several types of human
cancers and involved in tumor progression. The aim of this study was to investigate the clinical significance and
prognostic value of miR-452 expression in human osteosarcoma.
Methods: The expression of miR-452 was detected in 95 pairs of osteosarcoma specimens and adjacent noncancerous
bone tissues using quantitative RT-PCR (qRT-PCR) assay. Then, the association of miR-452 levels with clinicopathological
features and prognosis was analyzed. The roles of miR-452 in regulating osteosarcoma cell proliferation, apoptosis, and
invasion were evaluated in vitro.
Results: miR-452 expression was significantly downregulated in osteosarcoma tissues than those in corresponding
noncancerous bone tissues (P < 0.001). Decreased miR-452 expression was linked to larger tumor size, high tumor
grade, advanced clinical stage, distant metastasis, and shorter overall survival. Multivariate Cox regression analysis
confirmed that low level of miR-452 expression predicted poor prognosis independently. miR-452 overexpression in
MG-63 cells suppressed cell proliferation, promoted cell apoptosis, inhibited cell invasion, and led to decreased BMI1
protein levels.
Conclusions: These findings suggest that miR-452 downregulation may be involved in osteosarcoma formation and
progression and that miR-452 would serve as a novel prognostic biomarker for patients with this disease.
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Background
Osteosarcoma is one of the most common primary bone
tumors and occurs predominantly in children and young
adults [1]. With the development of multiple therapeutic
strategies including wide tumor excision, neoadjuvant or
adjuvant chemotherapy, and radiotherapy, the 5-year
survival of the non-metastatic patients has increased to
65 % [2]. However, osteosarcoma is very aggressive, and
approximately 40–50 % of patients will eventually de-
velop metastases, especially pulmonary metastases [3].
The prognosis of these patients is rather poor, and the
long-term survival rate is only 10–30 % [4]. Although
several genetic alterations have been reported to be linked
with osteosarcoma, the complex molecular mechanisms in
osteosarcoma pathogenesis remain largely unclear. There-
fore, the identification of novel diagnostic and prognostic
biomarkers and potential therapeutic targets is crucial for
improving the prognosis of osteosarcoma patients.
MicroRNAs (miRs) are short (about 22 nucleotides in
length), highly conserved small non-coding RNA mole-
cules that negatively regulate gene expression by binding
to target messenger RNAs (mRNAs) at their 3′-untrans-
lated region, leading to mRNA degradation or translation
suppression [5]. It is now clear that miRs play a vital role in
diverse biological processes, and deregulation or dys-
function of miRs is involved in a variety of human diseases
including cancer [6–8]. Emerging evidence demonstrates
that miRs participate in the regulation of cancer cell
growth, apoptosis, tumor angiogenesis, epithelial-mesen-
chymal transition, tumor invasion and metastasis, and
* Correspondence: manuwanglm@163.com
1Department of Orthopedics, The First Affiliated Hospital of Zhengzhou
University, Zhengzhou 450000, Henan Province, People’s Republic of China
Full list of author information is available at the end of the article
© 2016 Li and Wang. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Li and Wang World Journal of Surgical Oncology  (2016) 14:150 
DOI 10.1186/s12957-016-0900-y
chemotherapy resistance [9–11]. In osteosarcoma, aber-
rant expression of several miRs and their functions have
been reported. For example, miR-124 showed decreased
expression in osteosarcoma tissues, and its downregula-
tion was correlated with advanced clinical stage, positive
distant metastasis, and poor response to neoadjuvant
chemotherapy [12]. Low miR-217 and miR-646 expression
levels were unfavorable prognostic factors for overall sur-
vival of osteosarcoma patients [13]. Serum miR-191 and
miR-221 may be used as diagnostic biomarkers with the
ability to discriminate between patients with osteosarcoma
and the healthy cohort [14, 15]. Restoration of miR-154 in
osteosarcoma cells inhibited cell proliferation, colony for-
mation, migration, and invasion, as well as induced cell
cycle arrest at the G1 stage [16]. Furthermore, ectopic ex-
pression of miR-30a promoted chemotherapy-induced
apoptosis and enhanced chemosensitivity in osteosarcoma
[17]. Therefore, exploring the roles of miRs in osteosar-
coma development and its underlying mechanisms may
be helpful for its early diagnosis, accurate assessment, tar-
geted therapy, and prognosis evaluation.
miR-452 is a member of miR-224/miR-452 cluster.
Previous studies have proved that miR-224 is involved in
tumor formation and progression of several human can-
cers [18–20]. Recently, aberrant miR-452 expression has
been demonstrated in glioma [21], non-small cell lung
cancer (NSCLC) [22], bladder cancer [23], prostate can-
cer [24], urothelial carcinoma [25], and hepatocellular
carcinoma [26]. In these malignancies, miR-452 acts as a
potential oncogene or a candidate tumor suppressor in
different cellular contexts. However, very little is known
about the expression and clinical significance of miR-
452 in human osteosarcoma till now. Therefore, in the
current study, we examined miR-452 expression in
osteosarcoma specimens and paired adjacent nontumor-
ous tissues and investigated the correlation between
miR-452 expression and clinicopathological factors as
well as patient’s survival. We also explored the role of
miR-452 in the regulation of biological behaviors of
osteosarcoma cells.
Methods
Patients and tissue specimens
Paired fresh osteosarcoma specimens and noncancerous
bone tissues were collected from 95 patients at The First
Affiliated Hospital of Zhengzhou University (Zhengzhou
450000, Henan Province, People’s Republic of China) be-
tween January 2007 and December 2010. All the samples
were collected before any treatment. The specimens
were immediately frozen in liquid nitrogen and stored
at −80 °C until use. Table 1 shows the details of clinical
and pathological characteristics of the patients. The
diagnosis was confirmed by two senior pathologists.
The clinical stage was classified according to Enneking’s
staging system [27]. The follow-up data were available and
complete for each patient. The overall survival was calcu-
lated from the day of primary surgery to death or last
follow-up. The Research Ethics Committee of Zhengzhou
University approved our study, and all patients provided
written informed consent.
Cell culture and transfection
Human osteosarcoma MG-63 cells were purchased from
the Cell Bank of the Chinese Academy of Sciences
(Shanghai, China) and grown in Dulbecco’s modified Eagle
medium (DMEM; Life Technologies, Carlsbad, CA, USA)
supplemented with 10 % heat-inactivated fetal bovine
serum (FBS) at 37 °C in a humidified chamber with 5 %
carbon dioxide.
miR-452 mimics and negative control (miR-NC) were
obtained from GenePharma (China). MG-63 cells were
seeded into six-well plates and transfected with 50-nM
miR-452 mimics or miR-NC using Lipofectamine 2000
(Invitrogen, USA) in accordance with the manufacturer
protocol.
RNA extraction, reverse transcription, and real-time PCR
Total RNA isolation was performed using the miRNeasy
Mini Kit (Qiagen, Shanghai, China). Total RNA concen-
tration was assessed by measuring absorbance at 260 nm
using a NanoDrop spectrophotometer (ND-1000, Thermo
Scientific, Wilmington, USA). Complementary DNA
(cDNA) was synthesized from isolated RNA using
TaqMan MicroRNA Reverse Transcription Kit and
miRNA specific stem-loop primers (both from Applied
Biosystems, Foster City, CA, USA). Real-time PCR
was performed with a Taqman MicroRNA Assay Kit
(Applied Biosystems, Foster City, CA, USA) on ABI7500
real-time PCR detection system. Quantitative PCR was
conducted at 95 °C for 10 min followed by 40 cycles of
95 °C for 15 s and 60 °C for 60 s. All reactions were run in
triplicate, and miR-452 expression was normalized to U6
small nuclear RNA. The reverse transcription primer for
miRNA-452 was 5′-GTCGTATCCAGTGCGTGTCGTG
GAGTCGGCAATTGCACTGGATACGACTCAGTT-3′.
The PCR primers for miRNA-452 were 5′-GCGCAACT
GTTTGCAGAG-3′ (forward) and 5′-GTGCAGGGTCCG
AGG T-3′ (reverse) and those for U6 were 5′-CTCGCT
TCGGCAGCACA-3′ (forward) and 5′-AACGCTTCACG
AATTTGCGT-3′ (reverse). The relative amount of miR-
452 to U6 was calculated using the equation 2−ΔCt, where
ΔCT= (CTmiR-452−CTU6). The fold change of miR-452 in
osteosarcoma relative to the matched noncancerous bone
tissues was determined by the 2−ΔΔCt method.
Cell proliferation assay
Cell viability was evaluated using the MTT method. In
brief, MG-63 cells were seeded in a 96-well plate, and
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20 μl MTT solution (Sigma, USA) was added to the cul-
ture medium every 24 h, after transfection with miR-452
mimics or miR-NC. After 4 h, the medium was removed,
and 150 μl DMSO was added to dissolve the formazan.
Optical density was measured at 490 nm, using a plate
reader (Molecular Devices, Sunnyvale, CA, USA).
Flow cytometry analysis
After transfection with miR-452 mimics or miR-NC,
the MG-63 cells were washed and resuspended in
phosphate-buffered saline and then doubly stained
using the Annexin V-FITC/Propidium Iodide kit (BD
Biosciences, USA). After incubation in the dark for
15 min, cells were analyzed with a FACScan flow cytometer
(BD Biosciences, USA).
Cell invasion assay
Cell invasiveness was determined by using Transwell in-
sert chambers (8 μm pore size; Corning, USA). After
miRNA transfection, the MG-63 cells were collected and
resuspended in serum-free medium at a concentration
of 5 × 104 cells/ml and 200 μl cell suspensions were then
added into the upper chamber. The bottom chamber
was filled with 500 μl culture medium containing 10 %
FBS. After the incubation for 24 h, the non-invaded cells
were removed by a cotton swab, and cells on the lower
surface of the membrane were stained with crystal violet
and counted.
Western blot
Cells were lysed in RIPA buffer with protease inhibitors
and phosphatase inhibitors. The protein extracts were
Table 1 Association of miR-452 expression with clinicopathological factors in osteosarcoma
Clinicopathological features Number of cases miR-452 expression P
High Low
n (%) n (%)
Age
<20 years 70 33 (47.1 %) 37 (52.9 %) 0.352
≥20 years 25 15 (60.0 %) 10 (40.0 %)
Gender
Male 68 35 (51.5 %) 33 (48.5 %) 0.823
Female 27 13 (48.1 %) 14 (51.9 %)
Tumor size
>8 cm 39 14 (35.9 %) 25 (64.1 %) 0.012
≤8 cm 56 34 (60.7 %) 22 (39.3 %)
Anatomic location
Tibia/femur 66 31 (47.0 %) 35 (53.0 %) 0.374
Elsewhere 29 17 (58.6 %) 12 (41.4 %)
Tumor grade
Low 31 22 (71.0 %) 9 (29.0 %) 0.008
High 64 26 (40.6 %) 38 (59.4 %)
Histological type
Osteoblastic 33 19 (57.6 %) 14 (42.4 %) 0.830
Fibroblastic 21 10 (47.6 %) 11 (52.4 %)
Chondroblastic 14 6 (42.9 %) 8 (57.1 %)
Telangiectatic 15 8 (53.3 %) 7 (46.7 %)
Others 12 5 (41.7 %) 7 (58.3 %)
Enneking stage
I 24 20 (83.3 %) 4 (16.7 %) <0.001
II 48 23 (47.9 %) 25 (52.1 %)
III 23 5 (21.7 %) 18 (78.3 %)
Distant metastasis
Absent 72 43 (59.7 %) 29 (40.3 %) 0.001
Present 23 5 (21.7 %) 18 (78.3 %)
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loaded onto a 10 % sodium SDS-PAGE gel and transferred
to a PVDF membrane. The blots were probed with pri-
mary antibodies (anti-BMI1, 1:1000, Abcam, Cambridge,
UK) followed by the HRP-conjugated secondary antibody.
Following three Tris-buffered saline containing 0.1 %
Tween-20 (TBST) washes, the membranes were devel-
oped using ECL Plus (Millipore, MA, USA) and exposed
to X-ray film. GAPDH served as the loading control.
Statistics
All statistical analyses were performed using the SPSS
for Windows statistical software, version 16.0 (SPSS,
Chicago, IL, USA). Data are presented as the mean ±
standard deviation (SD). The differences between two
groups were analyzed using the Student’s t test. The re-
lationship between miR-452 levels and clinicopathologic
parameters was analyzed by chi-square test. Survival
curves were constructed with the Kaplan-Meier method
and compared by log-rank tests. The multivariate analyses
were evaluated with Cox proportional hazards models.
P < 0.05 was considered statistically significant.
Results
Decreased miR-452 expression in osteosarcoma samples
miR-452 expression was detected by using quantitative
real-time PCR (qRT-PCR) and normalized to U6. Figure 1a
shows decreased miR-452 expression in osteosarcoma
compared to matched adjacent noncancerous bone tis-
sues. Figure 1b shows that the relative level of miR-452 in
osteosarcoma specimens was significantly lower than that
in corresponding noncancerous bone tissues (mean ± SD,
4.03 ± 0.96 vs. 10.07 ± 1.98, P < 0.001).
Association between miR-452 expression and
clinicopathological factors
The median miR-452 expression level was used as a cut-
off value to divide all 95 patients into two groups: high
miR-452 expression group (n = 48) and low miR-452 ex-
pression group (n = 47). As shown in Table 1, we found
that low miR-452 expression was significantly associated
with larger tumor size (P = 0.012), high tumor grade
(P = 0.008), advanced Enneking stage (P < 0.001), and
distant metastasis (P = 0.001). However, there were no
significance between miR-452 expression and other
clinicopathological factors, such as age, gender, ana-
tomic location, and histological type.
Prognostic value of miR-452 in osteosarcoma
Then, we evaluated the prognostic significance of miR-452
expression in patients with osteosarcoma. As shown in
Fig. 2, patients in high miR-452 expression group had lon-
ger overall survival than those in low miR-452 expression
group (P < 0.001). Univariate Cox regression analysis dem-
onstrated that larger tumor size (P = 0.026), high tumor
grade (P = 0.015), positive distant metastasis (P = 0.002),
and advanced Enneking stage (P < 0.001) were also signifi-
cantly associated with shorter overall survival (Table 2).
Fig. 1 The relative expression levels of miR-452 in osteosarcoma specimens and matched adjacent noncancerous bone tissues. a The fold change
of miR-452 in osteosarcoma relative to the matched adjacent noncancerous bone tissues. b miR-452 expression was significantly lower in
osteosarcoma specimens than in the corresponding adjacent noncancerous bone tissues. miR-452 levels were calculated by the 2−ΔCt method
and normalized to U6 small nuclear RNA
Fig. 2 Osteosarcoma patients with low miR-452 expression had a
significantly shorter overall survival than those with high miR-452
expression (P < 0.001, log-rank test)
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Multivariate analyses using the Cox proportional hazards
regression model revealed that miR-452 expression
(relative risk (RR) 3.263; P = 0.018), tumor grade (RR 3.013;
P = 0.022), distant metastasis (RR 4.985; P = 0.003), and
Enneking grade (RR 5.458; P = 0.001) were independent
prognostic factors for overall survival of osteosarcoma.
The effects of miR-452 on the biological behavior of
MG-63 cells
Further, we assessed the biological role of miR-452 in
MG-63 cells. Transfection with miR-452 mimics resulted
in increased miR-452 level in MG-63 cells (P < 0.001,
Fig. 3a). The MTT assay showed that miR-452 overex-
pression obviously reduced MG-63 cell proliferation
Table 2 Cox regression analysis of factors associated with
overall survival in 95 osteosarcoma patients
Variable Univariate analysis Multivariate analysis
HR P value HR P value
Age 1.638 0.223 – –
Gender 1.126 0.772 – –
Anatomic location 1.695 0.178 – –
Tumor grade 3.572 0.015 3.013 0.022
Tumor size 3.108 0.026 1.165 0.082
Clinical stage 5.979 <0.001 5.458 0.001
Distant metastasis 4.392 0.002 4.985 0.003
miR-452 5.756 <0.001 3.263 0.018
Fig. 3 Effects of miR-452 on the biological behaviors of MG-63 cells. a qRT-PCR analysis confirmed increased miR-452 expression in MG-63 cells
after miR-452 mimics transfection. **P < 0.01. b MTT assay showed that miR-452 reduced cell proliferation in vitro. **P < 0.01. c Flow cytometric
analysis indicated that miR-452 promoted cell apoptosis. d Upregulation of miR-452 impeded cell invasion in MG-63 cells. **P < 0.01
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(Fig. 3b). Flow cytometry confirmed promoted apoptosis
in miR-452-overexpression MG-63 cells (Fig. 3c). Trans-
well invasion assay showed that miR-452 mimic trans-
fection impeded MG-63 cell invasion ability (Fig. 3d).
miR-452 could downregulate BMI1 expression in MG-63
cells
At last, we detected the changes in BMI1 protein levels
after miR-452 mimic transfection by western blot. The re-
sults showed that miR-452 overexpression in MG-63 cells
led to the downregulation of BMI1 protein levels (Fig. 4).
Discussion
Up to now, the exact mechanisms underlying osteosar-
coma are not fully understood. Identification of genetic
alterations would be important for the screening, diag-
nosis, and treatment of osteosarcoma. Accumulating evi-
dence has suggested the important roles of miRs in
tumor formation and progression. In the present study,
we revealed that the expression of miR-452 was signifi-
cantly reduced in osteosarcoma tissues, and reduced
miR-452 expression was significantly associated with lar-
ger tumor size, high tumor grade, advanced clinical
stage, and distant metastasis. Patients with low level of
miR-452 showed shorter overall survival than those with
high miR-452 level. miR-452 overexpression in MG-63
cells suppressed cell proliferation, promoted cell apop-
tosis, and inhibited cell invasion in vitro. Thus, loss of
miR-452 expression might be involved in osteosarcoma
development and serve as a novel biomarker for poor
prognosis.
Previous research has demonstrated the tumor-
suppressive function of miR-452 in several human ma-
lignancies. For example, Kristensen et al. reported that
miR-452 inhibited proliferation, migration, and invasion of
PC3 and DU145 prostate cancer cells [24]. He et al. showed
miR-452 downregulation in NSCLC tissues and its associ-
ation with positive tumor metastasis and advanced TNM
stage [22]. Zhang et al. revealed that upregulated miR-452-
suppressed NSCLC cell epithelial-mesenchymal transition
and further disrupted migration and invasion [28]. In hu-
man gliomas, decreased miR-452 expression was correlated
with shorter patient survival time [21]. Ectopic expression
of miR-452 reduced tumorigenicity in a nude mouse
xenograft model. Furthermore, overexpression of miR-
452 in MCF-7 breast cancer cells could significantly en-
hance cell apoptotic and increase chemosensitivity to
Adriamycin [29].
In contrast to the antitumor properties mentioned
above, miR-452 may act as a potential oncogene in blad-
der cancer and hepatocellular carcinoma [23, 25, 26].
Overexpression of miR-452 in HepG2 and QGY-7703
hepatocellular carcinoma cells dramatically accelerated
proliferation, induced cell cycle from G1 to S transition,
blocked apoptosis, and promoted cell migration and in-
vasion in vitro [26]. Increased miR-452 expression in
bladder urothelial carcinomas was associated with high
incidence of lymph nodes metastasis and poor prognosis
[25]. Thus, the function of miR-452 may be complex in
different cancer types, and the role of miR-452 should
be tumor specific and possibly dependent on the nature
of its targets.
Undoubtedly, miRs exert important functions in car-
cinogenesis by regulation of target gene expression [30].
In human cancers, some highly expressed miRs could
function as oncogenes by repressing tumor suppressor
genes, whereas low-expressed miRs could function as
tumor suppressors by negatively regulating oncogenes
[31]. Previous studies have reported several downstream
genes of miR-452, including BMI1 [22], CDKN1B [26],
IGF-1R [29], and KRAS [32]. BMI1 has been identified
as an oncogene in several cancers [33–36]. Wu et al. re-
vealed that overexpression of BMI1 could promote osteo-
sarcoma cell growth and induce resistance to cisplatin [37].
He et al. identified BMI1 as a direct target of miR-452 in
NSCLC [22]. Our study also observed decreased BMI1 pro-
tein levels in MG-63 cells after miR-452 overexpression.
However, there is no “one-to-one” connection between
miRs and target mRNAs. An average miR can have more
Fig. 4 miR-452 overexpression in MG-63 cells led to the downregulation
of BMI1 protein levels
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than 100 targets [38]. Conversely, several miRs can
converge on a single transcript target [39]. Therefore,
the potential regulatory circuitry afforded by miR-452
is enormous, and the accurate mechanisms on how
miR-452 influences osteosarcoma progression need fur-
ther clarification.
Conclusions
In summary, our research showed miR-452 downregula-
tion in osteosarcoma and its correlation with aggressive
clinicopathological features. Decreased miR-452 expression
might be an independent biomarker for poor prognosis.
Large-scale prospective studies are needed to confirm our
conclusion and clarify the mechanisms.
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